An observational study in Inflammatory Response to Glucose Sensors, sponsored by Corporacion Parc Tauli. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by Corporacion Parc Tauli · Observational
The aim of the study is to describe the inflammatory response to enzimatic glucose sensors after 10 days of use and to evaluate the relationship between the magnitude of the FBR (foreign body response) with the accuracy of the sensor (MARD)
Eighteen Type 1 DM patients are going to be included. Primary Objectives
Secondary Objectives
To describe the histology of tissue response. This description will include:
Each patient will have 1 glucose sensor inserted in the non-dominant arm. During the useful life of the sensor (10), a minimum of 4 capillary blood glucose determinations/day will be performed The sensor has a length of 8 mm and a diameter of 0.4 mm. All the necessary material will be provided, including a control diary to help the patient remember to carry out the self-control and set its time distribution.
On the last day of sensor use, it will be removed and a 4-mm punch skin biopsy will be performed 5 minutes later.
Tissue samples will be fixed in 4% formaldehyde solution, paraffin blocks made and sectioned. The resulting samples will be stained Semiquantitative determination of lymphocytes, neutrophils, mast cells, macrophages will be performed; fibrin, fibrosis, vascular proliferation and karyorrhexis
In all cases, a quantitative immunohistochemical study will be performed with x40 field counting with photographs and grid (Dako omnis with envision system) for:
Macrophages
The monitor-glucometer will be recovered for download and study of the record. The interstitial glucose - blood pairs will be made with those recorded but not used for callibration.
Glucose sensor values and insulin doses will be recover from tha medical application
Corporacion Parc Tauli is the lead sponsor of 163 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Eighteen people diagnosed with type 1 diabetes and treated with closed-loop systems
Exclusion Criteria:
after 10 days of use, the sensor is removed and the biopsy performed
Device: glucose sensor
skin biopsy (punch)
Number of Macrophages sourronding the sensor
Time frame: 10 days
MARD (CGM record for 10 days)
median absolute relative difference (BG- Sensor glucose)
Time frame: 10 days
Plan to share: Undecided
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Corporacion Parc Tauli